Reduced serum myostatin concentrations associated with genetic muscle disease progression
- 976 Downloads
Myostatin is a highly conserved protein secreted primarily from skeletal muscle that can potently suppress muscle growth. This ability to regulate skeletal muscle mass has sparked intense interest in the development of anti-myostatin therapies for a wide array of muscle disorders including sarcopenia, cachexia and genetic neuromuscular diseases. While a number of studies have examined the circulating myostatin concentrations in healthy and sarcopenic populations, very little data are available from inherited muscle disease patients. Here, we have measured the myostatin concentration in serum from seven genetic neuromuscular disorder patient populations using immunoaffinity LC–MS/MS. Average serum concentrations of myostatin in all seven muscle disease patient groups were significantly less than those measured in healthy controls. Furthermore, circulating myostatin concentrations correlated with clinical measures of disease progression for five of the muscle disease patient populations. These findings greatly expand the understanding of myostatin in neuromuscular disease and suggest its potential utility as a biomarker of disease progression.
KeywordsMyostatin Neuromuscular disease Biomarker Mass spectrometry
This work was supported by the EU funded projects BIO-NMD (No.241665), Neuromics (No. 305121) and RD-Connect (305444) and by the Medical Research Council (MRC) Centre for Neuromuscular Diseases Biobanks (Newcastle) which are part of EuroBioBank; we are grateful to Dan Cox and Mojgan Reza for technical support at the biobank and Karen Bettinson for support with phenotype data. We thank the Jain foundation for providing the LGMD2B patient samples and their helpful comments. We thank the Predictive Safety Testing Consortium of the Critical Path Institute for their contribution of healthy control serum samples.
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflicts of interest.
All studies involving human samples were conducted in accordance with the Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects and in accordance with a protocol which was approved by the local Institutional Review Board. All animals were handled in compliance with the NIH and institutional guidelines that were approved by the Institutional Animal Care and Use Committee Pfizer, Inc (Groton, CT, USA).
- 2.Anaya-Segura MA, Garcia-Martinez FA, Montes-Almanza LA, Diaz BG, Avila-Ramirez G, Alvarez-Maya I, Coral-Vazquez RM, Mondragon-Teran P, Escobar-Cedillo RE, Garcia-Calderon N, Vazquez-Cardenas NA, Garcia S, Lopez-Hernandez LB (2015) Non-invasive biomarkers for duchenne muscular dystrophy and carrier detection. Molecules (Basel, Switzerland) 20:11154–11172CrossRefGoogle Scholar
- 4.Ayoglu B, Chaouch A, Lochmüller H, Politano L, Bertini E, Spitali P, Hiller M, Niks EH, Gualandi F, Pontén F, Bushby K, Aartsma-Rus A, Schwartz E, Le Priol Y, Straub V, Uhlen M, Cirak S, 't Hoen PA, Muntoni F, Ferlini A, Schwenk JM, Nilsson P, Al-Khalili Szigyarto C (2014) Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies. EMBO mol med 6:918–936CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Hathout Y, Brody E, Clemens PR, Cripe L, DeLisle RK, Furlong P, Gordish-Dressman H, Hache L, Henricson E, Hoffman EP, Kobayashi YM, Lorts A, Mah JK, McDonald C, Mehler B, Nelson S, Nikrad M, Singer B, Steele F, Sterling D, Sweeney HL, Williams S, Gold L (2015) Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. Proc Natl Acad Sci USA 112:7153–7158CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Lakshman KM, Bhasin S, Corcoran C, Collins-Racie LA, Tchistiakova L, Forlow SB, St Ledger K, Burczynski ME, Dorner AJ, Lavallie ER (2009) Measurement of myostatin concentrations in human serum: circulating concentrations in young and older men and effects of testosterone administration. Mol Cell Endocrinol 302:26–32CrossRefPubMedGoogle Scholar
- 18.Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, Alfano LN, Berry K, Meadows E, Lewis S, Braun L, Shontz K, Rouhana M, Clark KR, Rosales XQ, Al-Zaidy S, Govoni A, Rodino-Klapac LR, Hogan MJ, Kaspar BK (2015) A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther J Am Soc Gene Ther 23:192–201CrossRefGoogle Scholar
- 19.Mendias CL, Lynch EB, Davis ME, Enselman ERS, Harning JA, DeWolf PD, Makki TA, Bedi A (2013) Changes in circulating biomarkers of muscle atrophy, inflammation and cartilage turnover in patients undergoing anterior cruciate ligament reconstruction and rehabilitation. Am J Sports Med 41:1819–1826CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Nakatani M, Takehara Y, Sugino H, Matsumoto M, Hashimoto O, Hasegawa Y, Murakami T, Uezumi A, Takeda S, Noji S, Sunada Y, Tsuchida K (2008) Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J Off Publ Fed Am Soc Exp Biol 22:477–487Google Scholar
- 23.Nigro V, Savarese M (2014) Genetic basis of limb-girdle muscular dystrophies: the 2014 update. Acta Myol Myopathies Card Off J Mediterr Soc Myol 33:1–12 (edited by the Gaetano Conte Academy for the study of striated muscle diseases) Google Scholar
- 28.Ratkevicius A, Joyson A, Selmer I, Dhanani T, Grierson C, Tommasi AM, DeVries A, Rauchhaus P, Crowther D, Alesci S, Yaworsky P, Gilbert F, Redpath TW, Brady J, Fearon KC, Reid DM, Greig CA, Wackerhage H (2011) Serum concentrations of myostatin and myostatin-interacting proteins do not differ between young and sarcopenic elderly men. J Gerontol Ser A Biol Sci Med Sci 66:620–626CrossRefGoogle Scholar
- 34.Spurney C, Shimizu R, Morgenroth LP, Kolski H, Gordish-Dressman H, Clemens PR (2014) Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy. Muscle Nerve 50:250–256CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, Flanigan KM, Pestronk A, Tawil R, Wolfe GI, Eagle M, Florence JM, King WM, Pandya S, Straub V, Juneau P, Meyers K, Csimma C, Araujo T, Allen R, Parsons SA, Wozney JM, Lavallie ER, Mendell JR (2008) A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 63:561–571CrossRefPubMedGoogle Scholar
- 39.Walker RG, Poggioli T, Katsimpardi L, Buchanan SM, Oh J, Wattrus S, Heidecker B, Fong YW, Rubin LL, Ganz P, Thompson TB, Wagers AJ, Lee RT (2016) Biochemistry and biology of GDF11 and myostatin: similarities, differences, and questions for future investigation. Circ Res 118:1125–1142CrossRefPubMedGoogle Scholar
- 40.Walter MC, Reilich P, Thiele S, Schessl J, Schreiber H, Reiners K, Kress W, Muller-Reible C, Vorgerd M, Urban P, Schrank B, Deschauer M, Schlotter-Weigel B, Kohnen R, Lochmuller H (2013) Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. Orphanet J Rare Dis 8:26CrossRefPubMedPubMedCentralGoogle Scholar
- 44.Zaharieva IT, Calissano M, Scoto M, Preston M, Cirak S, Feng L, Collins J, Kole R, Guglieri M, Straub V, Bushby K, Ferlini A, Morgan JE, Muntoni F (2013) Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy. PLoS One 8:e80263CrossRefPubMedPubMedCentralGoogle Scholar